Harrow

Harrow is a growing leader in the U.S. ophthalmic market. Our amazing journey has taken us from humble beginnings in 2014, when we first began commercial operations with our compounding pharmacy, to our current position with one of the largest ophthalmic product portfolios. Learn More at Harrow.com #Harrow #Ophthalmology #Optometry

Discover the ST difference and offer your patients affordable access through the Harrow Savings Card! Find out more about TobraDex® ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% at www.tobradexst.com TobraDex® ST is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or risk of bacterial ocular infection exists. TobraDex® ST is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. It is also contraindicated in patients with known hypersensitivity to any components of the medication. See safety information and full PI by visiting https://lnkd.in/ep38vKQu Hashtags: #TobraDexST #Harrow

The Harrow team continues to execute on its strategic plan and its mission to help eyecare professionals manage the preservation of their patients' sight by providing access to innovative and affordable medicines. #Harrow #eyecare #TRIESENCE #ophthalmology #retinaphysicians https://lnkd.in/eaduS3Rr

Planning to attend the AOA 2024 Conference in Nashville, TN? Come visit us at booth #1133 to learn more about Harrow and our product offerings. #harrow #AOA2024 #optometry #visitus

Great interview by the team at Healio with Global Ophthalmology Industry Leader and Harrow Board Member Adrienne Graves. https://lnkd.in/e-42yxNv

Discover Why ST Matters. Find out more about TobraDex® ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% at www.tobradexst.com #TobraDexST #Harrow TobraDex® ST is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or risk of bacterial ocular infection exists. TobraDex® ST is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures. It is also contraindicated in patients with known hypersensitivity to any components of the medication. See safety information and full PI by visiting https://lnkd.in/ep38vKQu

Harrow is pleased to share the results from its 52-week VEVYE ESSENCE-2 OLE study, demonstrating the long-term benefits to patients managing the signs and symptoms of dry eye disease with VEVYE! #Harrow #eyecare #VEVYE #cyclosporine #dryeyedisease #ophthalmology #optometry #pharmaceuticals https://lnkd.in/eTy4dvpg

Did you know that ILEVRO (nepafenac ophthalmic suspension) 0.3% has excellent market access coverage? With 74%* of all lives covered across commercial and Medicare Part D plans, doctors can confidently prescribe ILEVRO to their patients. Learn more about ILEVRO and its market access coverage today at www.ilevrohcp.com! *Data provided through MMIT and is current as of 2/2024. The information provided in this communication is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures. Nothing herein may be construed as an endorsement, approval, recommendation, representation, or warranty of any kind by any plan or insurer referenced herein.

Planning to attend the Kiawah Eye 2024 Conference on Kiawah Island, SC? Come visit us at tables #101 & #102 to learn more about Harrow and our product offerings. #harrow #KiawahEye2024 #ophthalmology #visitus

Check out the new peer-reviewed study released March 11, 2024: "The Effects of Low Viscosity Preservative-Free Chloroprocaine Ophthalmic Gel 3% versus BAK-Containing Tetracaine 0.5% on the Bactericidal Action of Povidone-Iodine." The full study is linked in this post.